Search

Displaying results 8041 - 8050 of 10000 in total
  1. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.

  2. Drug

    DLO6001

    go.drugbank.com/drugs/DB05178
    Experimental

    DL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinson’s disease symptoms including sialorrhoea and hyperhidrosis.

  3. Drug

    Vapendavir

    go.drugbank.com/drugs/DB05181
    Investigational

    BTA798 is an antiviral for the treatment of HRV, the common cold virus, known to cause significant clinical complications in sufferers of Asthma and Chronic Obstructive Pulmonary Disease.

  4. Drug

    SQ-109

    go.drugbank.com/drugs/DB05186
    Investigational

    SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. … Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.

    Synonyms: N-adamantanyl-N'-geranyl-ethylenediamineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  5. Drug

    Atl146e

    go.drugbank.com/drugs/DB05191
    Investigational

    ATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.

    Categories: Adenosine A receptor agonists, Heterocyclic Compounds, 2-Ring
  6. Drug

    MB07811

    go.drugbank.com/drugs/DB05192
    Investigational

    MB07811, a small molecule that is administered orally, has been extensively studied preclinically and is currently undergoing clinical testing. … MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides.

  7. Drug

    Ordopidine

    go.drugbank.com/drugs/DB05196
    Investigational

    ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses. … ACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects

  8. Drug

    CYC116

    go.drugbank.com/drugs/DB05198
    Investigational

    CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms. … Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition

    Categories: Heterocyclic Compounds, 1-Ring
  9. Drug

    LX1031

    go.drugbank.com/drugs/DB05199
    Investigational

    LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels. … LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders.

  10. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    It is a small molecule designed to act as a pharmacological chaperone that specifically binds, stabilizes, and facilitates the proper folding and trafficking of α-glucosidase (GAA). … AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.